Condition
Mixed Mesodermal (Mullerian) Tumor
Total Trials
2
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results
Data Visualizations
Phase Distribution
2Total
P 2 (1)
P 3 (1)
Trial Status
Unknown1
Active Not Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT02834013Phase 2Active Not Recruiting
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
NCT00954174Phase 3UnknownPrimary
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
Showing all 2 trials